SUZHOU, China, Dec. 8, 2020 /PRNewswire/ — Peijia Medical (HK Inventory Code: 09996) efficiently commenced the animal experiment for its mitral valve edge-to-edge restore product, advancing the event to the subsequent stage. The graduation of this experiment displays Peijia Medical’s long run dedication in growing impartial mental property merchandise. Reasonably than a “Me Too” product, the mitral valve restore product of Peijia Medical not solely avoids potential patent disputes, but additionally meets scientific wants by way of security, efficacy and surgeon expertise. Furthermore, it has taken one other strong stride within the innovation for the sector of structural coronary heart illness remedy.
Mitral valve interventional remedy is acknowledged as one of the difficult operations within the discipline of structural coronary heart illness. Globally, solely transcatheter edge-to-edge restore units have delivered superb scientific outcomes to this point. The transfemoral, edge-to-edge mitral valve restore has a variety ofindications, together with the traditional main mitral regurgitationand the secondary mitral regurgitation with complicated illness sorts and plenty of comorbidities.
Because the construction of mitral valve is complicated, with subvalvular buildings similar to chordae tendineae and papillary muscle, that are associated to left ventricular operate, it’s typically believed that mitral valve restore can protect the subvalvular buildings, whereas mitral valve alternative has a danger of potential injury to cardiac operate. Mitral valve interventional restore is considerably efficient, with minimally invasive trauma and fast restoration for sufferers. 5-year follow-up outcomes of MitraClip, for example, demonstrated that there was no important distinction in total survival fee or surgical restore. Peijia Medical has the impartial mental property proper and quite a lot of home and international patents for the mitral valve restore product which may obtain comparable degree of efficacy extra conveniently and successfully. A number of scientific research in animals have been initiated, and perioperative observations have demonstrated that the surgical procedure has passable security, simple operability and quick efficacy.
Peijia Medical focuses on the event of interventional therapies for structural coronary heart ailments, focusing on therapies for aortic, mitral, and tricuspid valve. Peijia Medical has accomplished affected person enrollment for each TaurusOne® and TaurusElite®, the primary and second era transcatheter aortic valve alternative (“TAVR”) merchandise, and is at the moment in registration course of for the 2 merchandise. The corporate can be actively getting ready the pre-clinical examine of TaurusNXT, the third era TAVR product.The graduation of the animal experiment for Peijia’s mitral valve restore product has additional expanded the corporate’s product pipeline within the discipline of valve interventional remedy, and laid a basis for the following FIM examine. Along with the transseptal mitral valve restore product, Peijia Medical can be conducting pre-clinical research on its mitral valve alternative product which is anticipated to start out human scientific trial subsequent yr. Peijia is growing a complete product pipeline that exhibits excellency in each width and depth. Peijia Medical will persist with impartial innovation, and to providing sufferers and medical doctors with complete interventional remedy merchandise and absolutely selling the event within the discipline of structural coronary heart illness remedy.
SOURCE Peijia Medical